IRLAHealthcare · BiotechnologyThe 9 Wall Street analysts covering IRulya Therapeutics, Inc. hold a median 12-month price target of $71 — +76.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 19 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores IRulya Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (84): Smaller than most of the companies we track.
Momentum (4): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IRLA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +76.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Oct 2026 | Raymond James | Initiates | Outperform | $72 |
| 9 Oct 2026 | Raymond James | Initiates | Outperform | — |
| 24 Sept 2026 | Rodman & Renshaw | Initiates | Buy | — |
| 24 Sept 2026 | Rodman & Renshaw | Initiates | Buy | $70 |
| 22 Sept 2026 | Citizens | Upgrade | Market Outperform | $77 |
| 22 Sept 2026 | Citizens | Upgrade | Market Outperform | — |
| 18 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $70 |
| 18 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 29 July 2026 | Oppenheimer | Initiates | Outperform | — |
| 29 July 2026 | Oppenheimer | Initiates | Outperform | $82 |
| 24 June 2026 | Leerink Partners | Initiates | Outperform | $4.00 |
| 24 June 2026 | Leerink Partners | Initiates | Outperform | — |
| 23 June 2026 | Cantor Fitzgerald | Initiates | Overweight | $4.00 |
| 23 June 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 30 Jan 2026 | Citizens | Downgrade | Market Perform | — |
| 30 Jan 2026 | D. Boral Capital | Downgrade | Hold | — |
| 29 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 15 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IRLA appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Oct 2026, IRulya Therapeutics, Inc. returned −89.1% against +15.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 97% of US stocks
Cheaper than 69% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 13% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
IRulya Therapeutics, Inc. has a market value of $35.0M and an enterprise value of $62.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$92.5M.
Free cash flow in the twelve months to 30 June 2026: −$47.0M.
Trailing P/E: −0.1×; forward P/E: −8.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
IRulya Therapeutics, Inc. employs 38 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IRulya Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
IRulya Therapeutics announced that senior management will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026.
Why it matters — The announcement provides IRLA watchers with information about an upcoming investor-facing company event.
Quince Therapeutics announced it is relaunching as IRulya Therapeutics, with a focus on clinical development of LAM-001. Its common stock is set to trade on Nasdaq under the symbol IRLA effective October 12, 2026, alongside leadership changes including a new CEO, CFO, and COO.
Why it matters — QNCX watchers may note the planned company-name and ticker change and the new leadership team.
Seeking Alpha published a transcript of Quince Therapeutics, Inc.’s shareholder/analyst call prepared remarks.
Why it matters — The transcript provides QNCX watchers with the company’s prepared remarks from a shareholder/analyst call.
Quince Therapeutics, Inc. discussed the clinical progress of its LAM-001 program in a Seeking Alpha transcript covering developments in pulmonary hypertension and bronchiolitis obliterans syndrome. The item presents the company's update on LAM-001's clinical advancement in these indications.
Why it matters — A QNCX watcher would care because this transcript provides insight into the clinical progress of LAM-001, one of the company's key pipeline programs.
Quince Therapeutics announced it will host a virtual key opinion leader event on September 28, 2026, to discuss the current treatment landscape for PH-ILD and BOS and the potential role of LAM-001 as a therapeutic option. The event was announced on September 17, 2026.
Why it matters — The event offers QNCX watchers an opportunity to learn how LAM-001 could fit into the treatment landscape for the serious, underserved conditions PH-ILD and BOS.
The 9 Wall Street analysts covering IRulya Therapeutics, Inc. have a median 12-month price target of $71, with estimates ranging from $65 to $98. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering IRulya Therapeutics, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IRulya Therapeutics, Inc. 34 out of 100 across roughly 4,600 US stocks as at 19 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Oct 2026, IRulya Therapeutics, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (84 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +76.3% from the last close, and Ticker Nerd's factor model ranks IRulya Therapeutics, Inc. 34 out of 100 as at 19 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering IRulya Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRLA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $98 over the next 12 months.
IRulya Therapeutics, Inc. returned -89.1% over the 12 months to 20 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
IRulya Therapeutics Inc. is a clinical-stage biopharmaceutical company developing disease-modifying therapies for serious and underserved pulmonary conditions.
The most recent item we track (GlobeNewsWire, 15 Oct 2026): "IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference". IRulya Therapeutics announced that senior management will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026.
IRulya Therapeutics Inc. is a clinical-stage biopharmaceutical company developing disease-modifying therapies for serious and underserved pulmonary conditions. Its primary program, LAM-001, is an investigational inhaled dry-powder formulation of rapamycin designed to address pulmonary diseases associated with dysregulated mammalian target of rapamycin activity. Current development areas include pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome following lung transplantation, and sarcoidosis-associated pulmonary hypertension. The company’s work combines drug formulation, inhalation delivery, and targeted clinical development to support potential treatments for complex respiratory disorders. IRulya Therapeutics Inc. operates within the biotechnology and specialty pharmaceuticals markets, serving an area where conventional treatment options may not adequately address underlying disease mechanisms. Its business is centered on advancing proprietary therapeutic candidates through clinical research and regulatory development, positioning the company as a focused participant in the pulmonary medicine sector.
CEO Dr. Brigette Roberts M.D. · 38 employees · United States · https://irulya.com
